The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
But now it must show that varseta-M can move into a registrational trial.
New data with pasritamig plus docetaxel support a recent pivotal start.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
